Table 4

5-year survival rates (percentage of patients)

A. 5-year OS rate
TestImmunohistochemical score of
02+3+
HercepTesta70.5%75.6%51.5%
Polyclonal antibody (DAKO)70.8%67.5%57.9%
NexES70.5%66.1%59.3%
CB-1169.1%81.8%56.9%
FISH
 No HER-2 amplification70.3%
 HER-2 amplification57.3%
B. 5-year DFS rate
TestImmunohistochemical score of
02+3+
HercepTesta57.7%78.33%45.4%
Polyclonal antibody (DAKO)58.2%61.9%53.9%
NexES58.2%65.5%51.9%
CB-11a58.2%100%44%
FISHa
 No HER-2 amplification62.7%
 HER-2 amplification48.8%
  • a Significant results.